Cardiome Pharma (CRME) Up Slightly on Test Publication

Cardiome Pharma Corp.

shares acquired 0.2% to $4.27, on the publication of results from an open label, single-center, randomized controlled study conducted by independent researchers at the Medical University of Vienna in Vienna, Austria, regarding its BRINAVESS® product. Share volume was 13,000, compared to an all-day average of 27,000